Related Experiment Video
Updated: Feb 17, 2026
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors
Lisa N Heppler1, David A Frank1
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Abstract:
Misregulation of transcription factors, including signal transducer and activator of transcription (STAT) proteins, leads to inappropriate gene expression patterns that can promote tumor initiation and progression. Under physiologic conditions, STAT signaling is stimulus dependent and tightly regulated by endogenous inhibitors, namely, suppressor of cytokine signaling (SOCS) proteins, phosphatases, and protein inhibitor of activated STAT (PIAS) proteins. However, in tumorigenesis, STAT proteins become constitutively active and promote the expression of progrowth and prosurvival genes. Although STAT activation has been widely implicated in cancer, therapeutic STAT inhibitors are still largely absent from the clinic. This review dissects the mechanisms of action of two families of endogenous STAT inhibitors, the SOCS and PIAS families, to potentially inform the development of novel therapeutic inhibitors.
Insights
Signal transducer and activator of transcription (STAT) proteins are crucial in cancer. This review explores suppressor of cytokine signaling (SOCS) and protein inhibitor of activated STAT (PIAS) families as potential therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Signal transducer and activator of transcription (STAT) proteins regulate gene expression.
- STAT signaling is tightly controlled by endogenous inhibitors like SOCS and PIAS proteins under normal conditions.
- Constitutive STAT activation is observed in cancer, promoting tumor growth and survival.
Purpose of the Study:
- To review the mechanisms of action of SOCS and PIAS protein families.
- To explore the potential of these endogenous STAT inhibitors for novel cancer therapeutics.
Main Methods:
- Literature review of STAT signaling pathways.
- Analysis of SOCS and PIAS protein families' inhibitory functions.
- Discussion of therapeutic implications for cancer treatment.
Main Results:
- STAT proteins are frequently dysregulated in cancer, leading to uncontrolled gene expression.
- SOCS and PIAS proteins are key endogenous regulators of STAT activity.
- Understanding their mechanisms can guide the development of targeted cancer therapies.
Conclusions:
- STAT signaling dysregulation is a hallmark of cancer.
- SOCS and PIAS proteins represent promising targets for developing novel STAT-inhibiting cancer drugs.
- Further research into these endogenous inhibitors could lead to new clinical treatments.
More Related Videos
09:58Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
Published on: June 27, 2020
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:20The JAK-STAT Signaling Pathway
01:24Regulation of Angiogenesis and Blood Supply
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:38Mitogens and the Cell Cycle